New Indication Alert: AbbVie Submits Applications To EMA And FDA for New UC Indication For Skyrizi® (Risankizumab)

AbbVie announced that it has submitted applications to the FDA and EMA for a new indication for Skyrizi® (risankizumab) to treat moderately to severely active ulcerative colitis (UC).  Skyrizi® is currently approved by both regulatory authorities to treat Crohn’s disease, psoriatic arthritis and psoriasis.